MLM Companies

Mannatech Review 2026

Glyconutrient MLM — publicly traded (NASDAQ: MTEX), declining revenue

2.2

HomeBusinessWatch Rating

Last updated: March 20, 2026

What is Mannatech?

Health supplement MLM founded by Samuel Caster in 1993. Known for glyconutrient products (Ambrotose) and the "glycobiology" health claims. Publicly traded (NASDAQ: MTEX). Revenue has been declining — approximately 119,000 associates and preferred customers as of Q3 2025.

Pros

  • Publicly traded (NASDAQ: MTEX) — financial transparency
  • Unique glyconutrient product category
  • Founded 1993 — over 30 years in business
  • Profitable in recent quarters despite declining revenue

Cons

  • Paid $7 million to settle Texas AG lawsuit over misleading health claims (2009)
  • Revenue and associate count declining significantly
  • Glyconutrient health claims not accepted by mainstream medical community
  • Products significantly overpriced vs. comparable supplements
  • Most associates earn minimal income

Rating Breakdown

Residual Income
2.0

Potential for ongoing passive income

Simplicity
2.0

Easy to understand and execute

Transparency
2.5

Clear about costs, requirements, and income

Community & Support
2.5

Quality of training and community

Value for Money
2.0

Worth the investment

Overall Rating
2.2

Frequently Asked Questions About Mannatech

Are Mannatech glyconutrients effective?
Mannatech's Ambrotose glyconutrient products are based on the concept of glycobiology — the study of sugars in cellular function. While glycobiology is a legitimate scientific field, independent research has not validated the specific health claims made for Mannatech's products. Mannatech paid a $7 million settlement with the Texas AG in 2009 for misleading health claims.
Is Mannatech a legitimate company?
Mannatech is a legitimate publicly traded company (NASDAQ: MTEX) that has been in business since 1993. However, like most MLMs, the income opportunity is challenging and the company has faced scrutiny over health claims. Revenue and associate counts have been declining.